Investment Thesis
Viatris faces severe operational challenges with a -24.6% net margin and -3.5B net loss, indicating fundamental profitability deterioration beyond one-time charges. While positive free cash flow of $1.9B and reasonable liquidity provide a financial buffer, the company's ability to return to profitability remains highly questionable given negative operating income and deteriorating returns on equity.
VTRS Strengths
- Positive free cash flow of $1.9B demonstrates operational cash generation capability
- Reasonable liquidity position with 1.38x current ratio supports near-term obligations
- Gross margin of 35.1% indicates retained pricing power in pharmaceutical business
- Moderate debt-to-equity ratio of 0.85x provides deleveraging flexibility
VTRS Risks
- Massive net loss of -$3.5B with negative operating margin of -18.6% signals structural profitability crisis
- Interest coverage ratio of -5.7x indicates inability to service debt from operating earnings
- Negative ROE of -23.9% and ROA of -9.5% reflect severe capital inefficiency and shareholder value destruction
- High long-term debt of $12.5B creates refinancing risk if operating performance doesn't improve
- Revenue essentially flat (+0.3% YoY) with no growth to offset operational losses
Key Metrics to Watch
- Operating income recovery - critical to achieving profitability and debt service capacity
- Net income trend - must show path to positive earnings to justify equity value
- Free cash flow sustainability - ensure operating cash generation continues despite losses
- Debt reduction progress - monitor whether company uses FCF to deleverage the $12.5B debt burden
- Gross margin stability - watch for pricing pressure or cost inflation in pharmaceutical segment
VTRS Financial Metrics
VTRS Profitability Ratios
VTRS Balance Sheet & Liquidity
VTRS 5-Year Financial Trend
5-Year Trend Summary: Viatris Inc's revenue has declined by 14% over the 5-year period, indicating business contraction. The most recent EPS of $0.05 reflects profitable operations.
VTRS Growth Metrics (YoY)
VTRS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.7B | $94.8M | $0.08 |
| Q2 2025 | $3.6B | -$4.6M | $0.00 |
| Q1 2025 | $3.2B | $113.9M | $0.09 |
| Q3 2024 | $3.7B | $94.8M | $0.08 |
| Q2 2024 | $3.8B | -$212.5M | $-0.18 |
| Q1 2024 | $3.7B | $113.9M | $0.09 |
| Q3 2023 | $3.9B | $331.6M | $0.27 |
| Q2 2023 | $3.9B | $264.0M | $0.22 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
VTRS Capital Allocation
VTRS SEC Filings
Access official SEC EDGAR filings for Viatris Inc (CIK: 0001792044)